October 2016
Volume 2, Issue 10
This issue looks at the pros and cons of open-access publishing, features updates from the ASH Meeting on Hematologic Malignancies, and shares tips for incorporating small-group instruction.
Table of Contents
October 2016
A Primer on Email Etiquette
Every day, more than 200 billion emails are sent and received, for an average of 122 emails sent and received, per user, in a...
October 2016
ASH’s Sickle Cell Disease Coalition, new Hematologist podcast, and more
‘It Takes a Village … and We Need a Village’
Report on Sickle Cell Disease Suggests That Current State of Treatment and Care is Inadequate...
NIH and EPA to Study Link Between Chemical Exposure and Childhood Leukemia, ASH announces...
Andrew Kung Appointed Chairman of Pediatrics at Memorial Sloan Kettering Cancer Center
Andrew L. Kung, MD, PhD, has been named the new chairman of the...
October 2016
Public Access: The Pros and Cons of Open-Access Publishing
Open access (OA), in which a scientific article is made freely available, in full, to anyone who wants to download it, seems at first...
Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A
Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For...
October 2016
Understanding Bone and Blood Marrow Transplants
Bone marrow is the soft tissue inside the bones that makes blood-forming cells known as blood stem cells. These grow into red blood cells...
Thinking Small
Anyone in medical education is familiar with Bloom’s Taxonomy, a pyramid-shaped model representing different types of learning objectives, from lower- to higher-order thinking (Figure...
Treating Myeloid Sarcoma After Induction Therapy
This month, Martin S. Tallman, MD, weighs in on the treatment for a patient with myeloid sarcoma after induction.
You Made the Call! We asked,...
October 2016
Healthy Lifestyle, Family Support May Help Explain How Octogenarians Are Able to Live With...
In the 1970s, patients with sickle cell disease (SCD) were not expected to live into adulthood, but today, patients may live into their 40s...
Corticosteroids and Intravenous Immune Globulin Lead to Similar Outcomes in Pregnant Women With Immune...
Approximately 30 to 35 percent of pregnant women with immune thrombocytopenia purpura (ITP) require therapeutic intervention during pregnancy, frequently with either corticosteroids or intravenous...
NHLBI Releases Strategy for Heart, Lung, Blood, and Sleep Research
The National Heart, Lung, and Blood Institute (NHLBI) announced its Strategic Vision to chart the course of heart, lung, blood, and sleep research over the next...
FDA Grants Pracinostat Breakthrough Designation for Older Patients With AML
The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for pracinostat in combination with azacitidine for patients with newly diagnosed acute myeloid...
FDA Approves Blinatumomab for Pediatric Acute Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) approved blinatumomab for pediatric and adolescent patients with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphocytic leukemia (ALL).
The...
World Federation of Hemophilia Creates Universal Case Report Form for Hemophilia Patients
The World Federation of Hemophilia (WFH) created the Universal Case Report Form (U-CRF) to collect and standardize data on relevant diagnosis, therapies, and outcomes...
FDA Approves Ofatumumab Combination for Relapsed Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) approved ofatumumab in combination with fludarabine and cyclophosphamide for patients with relapsed chronic lymphocytic leukemia (CLL).
The approval...
ABIM and ACCME Partner to Produce CME Finder Tool
The American Board of Internal Medicine (ABIM) and the Accreditation Council for Continuing Medical Education (ACCME) partnered to produce the CME Finder – a web-based tool...
Cancer Moonshot Panel Releases List of Top 10 Ways to Fight Cancer
The Cancer Moonshot Initiative’s Blue Ribbon Panel, a 28-member panel of advisers that includes top cancer researchers and patient advocates, presented a report to...
PET–CT Adapted Treatment Strategy Identifies Hodgkin Lymphoma Patients Who Can Safely Escalate or De-Escalate...
Understanding the short- and long-term toxicity of therapies for Hodgkin lymphoma (HL) is important for guiding treatment decisions, especially for patients in which the...
Ipilimumab Induces Complete Responses in Patients Who Relapse After Allogeneic Transplantation
More than one-third of patients with hematologic malignancies who undergo allogeneic hematopoietic cell transplantation (alloHCT) will relapse, and treatment options for this patient population...
October 2016
Improving Risk Stratification in Standard-Risk Myeloma Patients: Age, Bone Marrow Involvement Independently Predict Survival
Though the field of multiple myeloma (MM) has seen many advances in treatment in the past two years – including three new drug approvals...
Adolescents and Minority Groups Underrepresented in Cancer Clinical Trials
Adolescent and young adult (AYA) patients, defined as those between the ages of 15 and 29 years, and non-white patients are often under-represented in...
TP53 Mutation Associated With Poor, But Varied, Outcomes in Myelodysplastic Syndromes
The TP53 mutation, a common molecular abnormality in myeloid malignancies such as myelodysplastic syndromes (MDS), is associated with poor outcomes; however, it is unclear...
